Alar Pharmaceuticals Inc (6785) Fair Value & Analysis
Healthcare · TW · Market cap 7.9B TWD
Fair value as of: Jun 24, 2026
Analysis
Alar Pharmaceuticals Inc (6785) currently trades at 120.00 TWD, while our model-based Fair Value estimate is 107.93 TWD — implying the stock looks roughly 10.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Alar Pharmaceuticals Inc (6785) undervalued?
What is the fair value of 6785?
What is the quality score of 6785?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.